Triple Combination Therapy in High Risk Crohn's Disease (CD)
Status:
Active, not recruiting
Trial end date:
2022-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of triple combination therapy with an
anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist
(adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic
remission in participants with newly-diagnosed CD stratified at higher risk for
complications.